BET Bromodomain Inhibition Promotes Anti-Tumor Immunity by Suppressing PD-L1 expression

Restoration of anti-tumor immunity by blocking PD-L1 signaling using antibodies has proven to be beneficial in cancer therapy. Here we show that BET bromodomain inhibition suppresses PD-L1 expression and limits tumor progression in ovarian cancer. CD274 (encoding PD-L1) is a direct target of BRD4-me...

詳細記述

保存先:
書誌詳細
出版年:Cell Rep
主要な著者: Zhu, Hengrui, Bengsch, Fee, Svoronos, Nikolaos, Rutkowski, Melanie R., Bitler, Benjamin G., Allegrezza, Michael J., Yokoyama, Yuhki, Kossenkov, Andrew V., Bradner, James E., Conejo-Garcia, Jose R., Zhang, Rugang
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5177024/
https://ncbi.nlm.nih.gov/pubmed/27626654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.08.032
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料